98%
921
2 minutes
20
Trichomoniasis is a globally prevalent sexually transmitted disease; however, comprehensive data on its global prevalence and incidence are relatively limited. In this study, we systematically retrieved relevant articles from PubMed, Google Scholar, Scopus, Ovid-Medline, and Web of Science to analyze the prevalence of Trichomonas vaginalis and its association with various infection risk factors. Among 5,437 publications released between 1992 and 2023, 425 articles focusing on the epidemiology of T. vaginalis were identified. The results revealed a global prevalence rate of T. vaginalis of 8% (95% CI: 7%-10%), with country-specific rates ranging from 1% to 35%. The prevalence of T. vaginalis was significantly higher in the behavioral subgroups, including smoking, drug use, and not using condoms, compared to the non-infection group, with a pooled odds ratio (OR) of 1.67 (95% CI: 1.39-2.0). Furthermore, the prevalence of T. vaginalis was significantly higher in the group with other sexually transmitted infections (STIs), including HIV, HSV, and Chlamydia infection compared to the non-infection group, with a pooled OR of 2.01 (95% CI: 1.48-2.72). Finally, socioeconomic factors such as being unmarried, having a low income, and unstable employment were associated with an increased risk of T. vaginalis infection, with a pooled OR of 1.36 (95% CI: 1.10-1.66). This study has significant public health relevance for the prevention and control of trichomoniasis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12386857 | PMC |
http://dx.doi.org/10.1051/parasite/2025051 | DOI Listing |
J Microbiol Immunol Infect
September 2025
Department of Pediatrics, MacKay Children's Hospital and MacKay Memorial Hospital, Taipei, Taiwan.
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants and young children. The COVID-19 pandemic significantly disrupted global RSV epidemiology. This study aimed to investigate the impact of the pandemic on RSV epidemiology in northern Taiwan from 2018 to 2023.
View Article and Find Full Text PDFJ Epidemiol
September 2025
Department of Social Medicine, National Center for Child Health and Development.
BackgroundIn 2023, a collaborative UNICEF-WHO group introduced the concept of small vulnerable newborns (SVNs) to improve the identification of newborns at increased risk of adverse outcomes and to guide more effective preventive strategies. However, global data on the prevalence of SVNs remains scarce. This study aimed to examine secular trends in the prevalence of SVNs and their three subgroups, namely term small for gestational age (SGA), preterm SGA, and preterm non-SGA, in the Japanese population.
View Article and Find Full Text PDFInfect Dis Clin North Am
September 2025
Divison of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A07, Atlanta, GA 30333, USA.
This article describes the epidemiology of Clostridioides difficile infection (CDI) by outlining common approaches to CDI surveillance, including the application of a case definition and risk adjustment, and summarizing recent global trends in the incidence or prevalence of CDI. The article also describes important risk factors for CDI and recent advancements in identifying sources of C difficile.
View Article and Find Full Text PDFClin Nutr ESPEN
September 2025
Department of Epidemiology, University of Iowa, Iowa City, IA.
Background & Aims: People with multiple sclerosis (MS) may be predisposed to malnutrition as several malnutrition risk factors are common among this group; however, evidence on malnutrition in MS is sparse. Therefore, the aim of the present study is to explore what is known about malnutrition in MS.
Methods: A scoping review was performed in 5 databases (Ovid Medline, Embase, Cochrane Central, Scopus, and the Web of Science Core Collection) in February 2024.
J Affect Disord
September 2025
Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea; Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; D
Background: Major depressive disorder (MDD), anxiety disorders, and self-harm are substantial contributors to the global disease burden, exacerbated by the COVID-19 pandemic.
Methods: We used Global Burden of Diseases Study (GBD) 2021 to estimate global, regional, and national prevalence, mortality, and disability-adjusted life years (DALYs) for MDD, anxiety disorders, and self-harm from 1990 to 2021. Annual percentage changes were calculated for pre-pandemic (1990-2019) and pandemic (2019-2021) periods.